Mesothelioma

Sixty percent of the total — or $5.55 million — is to be paid by John Crane Inc., a multinational company that manufactured gaskets and sealants made with asbestos.

Garlock Sealing Technologies, a Palmyra, N.Y., company that competed with John Crane in making the same products, had already settled for an undisclosed amount with Oney before the case went to trial.

Archibald Wallace, a Richmond attorney who represented John Crane Inc., could not immediately be reached last Thursday.

The company is expected to appeal the jury verdict.

Attorneys for the Oney family said between 1963 and 1973, Vaughn Oney was sometimes in contact with asbestos daily.

He retired in 1994, in his early fifties and, according to attorneys representing the family, in good health.

But He was diagnosed in 2004.

"He needed an incredible amount of narcotics to endure the pain every day,'' said Robert Hatten, who represented Oney.

"The last six weeks of his life, he was in horrific condition.'' The verdict comes less than one year after the court awarded $10.4 million to the family of Buddy Jones, another Newport News shipyard worker who died of the disease.

"The asbestos industry knew that asbestos fibers could kill you,'' Hatten said.

"They knew how to prevent it, they knew how to test for it, they knew how...

ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.About Alfacell CorporationSafe HarborThis press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions.

Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements.

Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission.

By making these forward-looking statements, ...

In the fourth calendar quarter of 2007, the Company plans to test whether AmpTide(TM) interferes with the tumor-promoting activity of matriptase.

Such interference may be useful in the treatment of a variety of cancers, including WntTide for Osteoporosis In November 2006, the Company licensed Mesd from Washington University, St.

Louis, for the treatment of osteoporosis and cancer.

In the second half of calendar 2007, the Company will be testing the ability of Mesd and engineered Mesd-based peptides, which we call WntTide, acting through LRP5, a known determinant of bone density, to combat osteoporosis and increase bone density in a preclinical study.

Appointment of The Ruth Group as Investor Relations Firm Effective April 1, 2007, the Company appointed the New York-based investor relations firm, The Ruth Group, headed by Carol Ruth, a 39-year veteran in the investor relations field.

"We are excited to be working with a highly-regarded firm such as The Ruth Group, to help expand our investor and public outreach and be an advisor on our strategic planning team," said Kim Tsuchimoto, the Company's Chief Financial Officer.

Other Updates The Company continues to make progress with building its intellectual property portfolio.

Raptor currently has five patent applications in review...